3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

The CIR “Credit Impôt Recherche” or French Research Tax Credit is a corporate tax relief measure that allows French companies to declare innovative research costs and obtain a significant reduction on their tax bill.

This renewal allows 3P’s French customers the opportunity to receive an important percentage of their R&D costs in tax credits. Therefore, 3P Biopharmaceuticals continues to bring added-value to their French clients thanks to this opportunity to increase the quality, safety and efficacy of their biologic drugs.

3P Biopharmaceuticals already counts with a strong French client portfolio at different stages of their biologics development who have embraced this interesting incentive over the last years.

3P Biopharmaceuticals successfully extends its French CIR certificate for 2020-2024.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is wonderful news to renew CIR certificate for another four years to confirm 3P Biopharmaceuticals, once again, as a valuable and competitive CDMO partner for French biotech and pharma companies interested in developing biologics.

3P Biopharmaceuticals once again demonstrates its capacity to carry out processes development and manufacturing of molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.

Our dedicated team of specialists will be happy to discuss any of your CDMO needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.